Olink to Science

Utilizing proteogenomics technology for novel drug target discovery

Jul 13, 2021 3:24:44 PM / by Olink posted in Precision medicine, Drug discovery & development

0 Comments

High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation. This has the potential to revolutionize the drug discovery process and a major academia-industry consortium is at the forefront of efforts to do just that.

Read More

Olink Explore 1536 measures over 1500 proteins

Mar 1, 2021 9:30:00 AM / by Olink posted in Wider proteomics studies, Plasma, Biomarkers, Multiomics, Basic research, Precision medicine, Olink technology

0 Comments

 

Advances in genomics have opened the doors to large-scale, high-throughput acquisition of biological data. As a result, our understanding of biology has increased substantially, so much so that this phase in history has been termed the 'DNA revolution'. But what about the workhorses of the body? What more could our proteome reveal? Just as genomics underwent a revolution, proteomics is having its own revolution right now. Introducing Olink Explore 1536, a product created for the screening and discovery of novel protein biomarkers.

Read More

How the proteome behaves in healthy individuals

Feb 15, 2021 9:30:00 AM / by Olink posted in Wellness, Plasma, Multiomics, Clinical research, Precision medicine, Longitudinal Data

0 Comments

 

To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations. This especially applies to the stability of molecular profiles among healthy individuals over time, as this will clarify what qualifies as a ‘normal range’ of clinical parameters in health and disease research. The following study by Tebani et al. (2020) conducted a longitudinal analysis of the blood profiles from 100 healthy individuals to understand how they varied both between different individuals, and within an individual over time.

Read More